A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Phase: Phase I-II clinical trials
Principal Investigator: Prof. Corradini Paolo
Main Facility: Ematologia
Drug: GSK5926371, tricpsecific antibody anti CD19, CD20 CD3
Pathologies: Hematologic malignancies (Lymphomas, Leukemias, Myelomas, and others)
ClinicalTrials.gov: Read the details about clinical trials
Non-Hodgkin B-cell lymphoma (B-NHL) is a type of cancer that affects B cells, which are part of the immune system. These B cells divide and grow abnormally, leading to the formation of tumors.
Current treatments, including chemotherapy and targeted therapies, can be effective; however, some patients experience a return of the disease (relapse) or do not respond to treatment (refractory disease). These therapies also face challenges, including the development of resistance by cancer cells and the occurrence of side effects.
This study aims to address these unmet needs by evaluating a new investigational drug called GSK5926371, which has been designed to specifically kill cancerous B cells.
Researchers will assess the drug's safety, how it is processed by the body (pharmacokinetics), and identify early signs of its effectiveness against relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).
Last update: 10/11/2026